Welcome to the e-CCO Library!

P437: Higher adalimumab maintenance regimens are more effective than standard maintenance doses in Crohn’s disease patients who have failed infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Narula1*, T. Greener2, K. Boland2, A.H. Steinhart2, M. Silverberg2

Created: Thursday, 21 February 2019, 9:14 AM
P437: Hyperbaric oxygen therapy for Inflammatory Bowel Disease – a systematic review
Year: 2021
Source: ECCO'21 Virtual
Authors: Meima - van Praag, E.(1);Lansdorp, C.(2);Smeekes, G.(1);Gecse, K.(3);van Hulst, R.(2);Buskens, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P437: Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.
Year: 2022
Source: ECCO'22
Authors: Risto, A.(1);Andersson, R.E.(1);Landerholm, K.(1);Bengtsson, J.(2);Block, M.(2);Myrelid, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P437: Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Calafat*1, M. Mañosa1,2, J. Panes2,3, P. Nos2,4, E. Iglesias5, I. Vera6, A. López-Sanromán7, J. Guardiola8, C. Taxonera9, M. Mínguez10, M. D. Martín11, L. de Castro12, S. Riestra13, M. Rivero14, E. García-Planella15, X. Calvet2,16, S. García-López17, M. Andreu18, F. Gomollón19, J. Barrio20, M. Esteve2,21, A. Rodríguez22, J. P. Gisbert2,23, A. Gutierrez24, J. Hinojosa25, F. Argüelles26, D. Busquets27, L. Bujanda28, J. Lázaro29, B. Sicilia30, O. Merino31, P. Martínez32, F. Bermejo33, R. Lorente34, M. Barreiro-de-Acosta35, C. Rodríguez36, M. Fe37, M. Piqueras38, P. Romero39, E. Rodríguez40, Ó. Roncero41, J. Llaó42, G. Alcaín43, J. Riera44, M. Sierra45, L. I. Fdez. Salazar46, V. Jair47, M. Navarro48, M. A. Montoro49, C. Muñoz, A. J. Lucendo, M. Van Domselaar, I. Moraleja, J. M. Huguet, L. Ramos, P. Ramírez, P. Almeda, R. Pajares, S. Khorrami, R. E. Madrigal, E. Sesé, A. M. Trapero, J. Legido, Á. Abad, F. Cañete1,2, E. Cabré1,2, E. Domènech1,2

Created: Friday, 22 February 2019, 9:41 AM
P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Barberio1, F. Zingone1, A. Ferronato2, A. Buda3, P. Melatti1, A. Gubbiotti1, D. Massimi1, C. Casadei1, L. Cingolani4, E.V. Savarino1

Created: Thursday, 30 January 2020, 10:12 AM
P438: Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Van de Vondel S.*1, Baert F.2, Reenaers C.3, Bossuyt P.4, Hindryckx P.5, Vanden Branden S.6, Amininejad L.7, Dewint P.8, Rahier J.F.9, Ferrante M.1 Belgian IBD Research and Development

Created: Wednesday, 20 February 2019, 10:36 AM
P438: Efficacy and safety of ustekinumab for Ulcerative Colitis through 4 years in Asian patients: Final results from the sub-population of UNIFI long-term extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hisamatsu, T.(1)*;Kim, H.J.(2);Motoya, S.(3);Suzuki, Y.(4);Ohnishi, Y.(5);Marano, C.(6);Imai, Y.(7);Saadoun, C.(8);Zhuo, J.(9);Kawamura, S.(8);
Created: Friday, 14 July 2023, 11:05 AM
P438: Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are rare but insidious adverse events: data from a large single-centre cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. S. Macaluso*1, C. Sapienza1, M. Ventimiglia1, M. Cottone1, A. Orlando1

Created: Friday, 22 February 2019, 9:41 AM
P438: Maladaptive decision-making is associated with psychological morbidity in people with Inflammatory Bowel Disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Grinsted Tate, L.(1);Johnson, L.(1);Jones, G.(2);Lobo, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P438: Reinduction with ustekinumab in Crohn’s disease patients with a loss of response to treatment
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Heron1*, S. Restellini1,2, T. Bessissow1, C. Lemieux1, P. Lakatos1, G. Wild1, E. Seidman1, A. Bitton1, W. Afif1

Created: Thursday, 21 February 2019, 9:14 AM
P438: The Efficacy and Safety of ustekinumab Therapy in refractory Inflammatory Bowel Disease (IBD) patients with co-morbidities and old age.
Year: 2022
Source: ECCO'22
Authors: Davies, B.(1);Lodhia, M.(1);Abdalla, B.(1);Gupta, V.(1);
Created: Friday, 11 February 2022, 3:52 PM
P438: The inflammatory bowel disease disability index applied to ileal pouch anal anastomoses in New Zealand
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Lee1, A. McCombie*1, 2, R. Gearry3, F. Frizelle1, J. Williman4, R. Leong5, T. Eglinton1

Created: Friday, 22 February 2019, 9:49 AM
P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Bouhnik1, X. Roblin2, R. Mrad3, X. Hebuterne4, D. Laharie5, C. Tanasa Stefanescu1, S. Nancey6, A. Boureille7, A. Amiot8, N. Sebbah9, L. Peyrin Biroulet10

Created: Thursday, 30 January 2020, 10:12 AM
P439: Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Thi A.A.*1, Bouri S.1, Wolfson P.1, Owen L.1, Abbara A.2, John L.2, Davidson R.2, Hart A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P439: Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. J. Casanova*1, M. Chaparro1, M. Mínguez2, E. Ricart3, C. Taxonera4, S. García-López5, J. Guardiola6, A. López-San Román7, E. Iglesias8, B. Beltrán9, B. Sicilia10, M. I. Vera11, J. Hinojosa12, S. Riestra13, E. Domènech14, X. Calvet15, J. L. Pérez-Calle16, M. D. Martín-Arranz17, X. Aldeguer18, M. Rivero19, D. Monfort20, J. Barrio21, M. Esteve22, L. Márquez23, R. Lorente24, E. García-Planella25, L. de Castro26, F. Bermejo27, O. Merino28, A. Rodríguez-Pérez29, P. Martínez-Montiel30, M. Van Domselaar31, G. Alcaín32, M. Domínguez-Cajal33, C. Muñoz34, F. Gomollón35, L. Fernández-Salazar36, M. F. García-Sepulcre37, I. Rodríguez-Lago38, A. Gutiérrez39, F. Argüelles-Arias40, C. Rodriguez41, G. E. Rodríguez42, L. Bujanda43, J. Llaó44, P. Varela45, L. Ramos46, J. M. Huguet47, P. Almela48, P. Romero49, M. Navarro-Llavat, Á. Abad, P. Ramírez-de la Piscina, A. J. Lucendo, E. Sesé, R. E. Madrigal, M. Charro, A. García-Herola, R. Pajares, S. Khorrami, J. P. Gisbert1

Created: Friday, 22 February 2019, 9:41 AM
P439: Effectiveness of a training programme on motivational interviewing skills applied to inflammatory bowel disease management
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Daperno*1, F. Mocciaro2, F. Caprioli3, M. Fantini4, S. Leone5, M. Comberlato6, V. Quercia7

Created: Friday, 22 February 2019, 9:49 AM
P439: Effectiveness of Ustekinumab on Crohn's disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Year: 2021
Source: ECCO'21 Virtual
Authors: Macaluso, F.(1);Fries, W.(2);Viola, A.(2);Costantino, G.(2);Muscianisi, M.(2);Cappello, M.(3);Guida, L.(3);Giuffrida, E.(3);Magnano, A.(4);Pluchino, D.(4);Ferracane, C.(4);Magrì, G.(5);Di Mitri, R.(6);Mocciaro, F.(6);Privitera, A.C.(7);Camilleri, S.(8);Garufi, S.(8);Renna, S.(1);Casà, A.(1);Scrivo, B.(1);Ventimiglia, M.(1);Orlando, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P439: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panés, J.(1)*;Louis, E.(2);Bossuyt, P.(3);Joshi, N.(4);Lee, W.J.(4);Lacerda, A.(4);Remple, V.(4);Xuan, S.(4);Loftus Jr. , E.V.(5);
Created: Friday, 14 July 2023, 11:05 AM
P439: Monitoring inflammatory Bowel disease activity in a virtual biologic clinic: The effects of proactive therapeutic drug monitoring on patient reported outcome measures
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Mc Gettigan*, M. McNally, C. Deane, A. Keogh, R. Costello, E. Slattery

Created: Thursday, 21 February 2019, 9:14 AM
P439: Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.
Year: 2022
Source: ECCO'22
Authors: Roblin, X.(1);Bastide, L.(1);veyrard, P.(1);berger, A.E.(2);Paul, S.(2);
Created: Friday, 11 February 2022, 3:52 PM